M&A Deal Summary

Pfizer Acquires Medivation

On August 22, 2016, Pfizer acquired life science company Medivation for 14.0B USD

Acquisition Highlights
  • This is Pfizer’s 25th transaction in the Life Science sector.
  • This is Pfizer’s 6th largest (disclosed) transaction.
  • This is Pfizer’s 22nd transaction in the United States.
  • This is Pfizer’s 9th transaction in California.

M&A Deal Summary
Date 2016-08-22
Target Medivation
Sector Life Science
Buyer(s) Pfizer
Deal Type Add-on Acquisition
Deal Value 14.0B USD
Advisor(s) J.P. Morgan Securities
Evercore Group (Financial)
Cooley
Wachtell, Lipton, Rosen & Katz (Legal)

Target

Medivation

San Francisco, California, United States
Medivation, Inc. is a biopharmaceutical company focused on the development and commercialization of medically innovative therapies to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their families.

Search 201,292 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Pfizer

New York, New York, United States
Category Company
Founded 1849
Sector Life Science
Employees8,300
Revenue 58.5B USD (2023)
DESCRIPTION
Pfizer office in Lake Forest, Illinois.
Pfizer office in Lake Forest, Illinois.

Pfizer is a global pharmaceutical company that is involved in the discovery, development, manufacture, and marketing of a wide range of healthcare products, including medicines and vaccines. The company's portfolio includes treatments across a broad spectrum of areas such as oncology, cardiology, neurology, and infectious diseases, among others. Pfizer was founded in 1849 and is based in New York, New York.

DEAL STATS #
Overall 29 of 44
Sector (Life Science) 25 of 39
Type (Add-on Acquisition) 22 of 31
State (California) 9 of 14
Country (United States) 22 of 32
Year (2016) 4 of 5
Size (of disclosed) 6 of 22
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2016-08-01 Bamboo Therapeutics

Chapel Hill, North Carolina, United States

Bamboo Therapeutics, Inc. is a privately held biotechnology company focused on developing gene therapies for the potential treatment of patients with certain rare diseases related to neuromuscular conditions and those affecting the central nervous system.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2016-08-24 AstraZeneca - Small Molecule Anti-Infective Business

London, United Kingdom

AstraZeneca - Small Molecule Anti-Infective Business includes the commercialization and development rights to the newly approved EU drug Zavicefta™ (ceftazidime-avibactam), the marketed agents Merrem™/Meronem™ (meropenem) and Zinforo™ (ceftaroline fosamil), and the clinical development assets aztreonam-avibactam (ATM-AVI) and CXL.

Buy $550M
Mergr

Product

Company

Legal